Probiotics and the management of inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 10, Issue 3, 2004, Pages 286-299

  Fedorak, Richard N ^a   Madsen, Karen L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bifidobacteria; Crohn's disease; Inflammatory bowel disease; Lactobacilli; Pouchitis; Probiotics; Ulcerative colitis; VSL 3

Indexed keywords

CIPROFLOXACIN; CORTICOSTEROID DERIVATIVE; CULTURA; GENTAMICIN; HYDROCORTISONE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; METRONIDAZOLE; MUTAFLOR; NISSLE 1917; PLACEBO; PREBIOTIC AGENT; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; RIFAXIMIN; YAKULT;

ANTIMICROBIAL ACTIVITY; APOPTOSIS; BIFIDOBACTERIUM; CLINICAL TRIAL; COLONY FORMING UNIT; CROHN DISEASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENTERITIS; ESCHERICHIA COLI; GENETIC ENGINEERING; HUMAN; ILEITIS; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INTESTINE LYMPHATIC TISSUE; LACTOBACILLUS; MAINTENANCE THERAPY; MOUSE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RAT; REVIEW; SACCHAROMYCES BOULARDII; STREPTOCOCCUS SALIVARIUS; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS;

ACUTE DISEASE; BIFIDOBACTERIUM; CLINICAL TRIALS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; LACTOBACILLUS; POUCHITIS; PROBIOTICS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 2442495410     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200405000-00018     Document Type: Review

References (125)

1. Marteau PR. Probiotics in clinical conditions. Clin Rev Allergy Immunol. 2002;22:255-273.
2. Marteau P, Seksik P, Jian R. Probiotics and intestinal health effects: a clinical perspective. Br J Nutr. 2002;88(suppl 1):S51-S57.
3. Marteau P, Boutron-Ruault MC. Nutritional advantages of probiotics and prebiotics. Br J Nutr. 2002;87(suppl 2):S153-S157.
4. Tuohy KM, Probert HM, Smejkal CW, et al. Using probiotics and prebiotics to improve gut health. Drug Discov Today. 2003;8:692-700.
5. Bengmark S. Use of some pre-, pro- and synbiotics in critically ill patients. Best Pract Res Clin Gastroenterol. 2003;17:833-848.
6. Cummings JH, Macfarlane GT. Gastrointestinal effects of prebiotics. Br J Nutr. 2002;87(suppl 2):S145-S151.
7. Steidler L. Genetically engineered probiotics. Best Pract Res Clin Gastroenterol. 2003;17:861-876.
8. Schley PD, Field CJ. The immune-enhancing effects of dietary fibres and prebiotics. Br J Nutr. 2002;87(suppl 2):S221-S230.
9. Kolida S, Tuohy K, Gibson GR. Prebiotic effects of inulin and oligofructose. Br J Nutr. 2002;87(suppl 2):S193-S197.
10. McCartney AL. Application of molecular biological methods for studying probiotics and the gut flora. Br J Nutr. 2002;88(suppl 1):S29-S37.
11. Saavedra JM, Tschernia A. Human studies with probiotics and prebiotics: clinical implications. Br J Nutr. 2002;87(suppl 2):S241-S246.
12. Tamboli CP, Caucheteux C, Cortot A, et al. Probiotics in inflammatory bowel disease: a critical review. Best Pract Res Clin Gastroenterol. 2003;17:805-820.
13. Teitelbaum JE, Walker WA. Nutritional impact of pre- and probiotics as protective gastrointestinal organisms. Annu Rev Nutr. 2002;22:107-138.
14. Shanahan F. Turbo probiotics for IBD. Gastroenterology. 2001;120: 1297-1298.
15. Shanahan F. Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future. Br J Nutr. 2002;88(suppl 1):S5-S9.
16. Hart AL, Stagg AJ, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2003;36:111-119.
17. Schultz M, Scholmerich J, Rath HC. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Dig Dis. 2003; 21:105-128.
18. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology. 2001;120:622-635.
19. Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr. 2002;88(suppl 1):S39-S49.
20. Kraehenbuhl JP. Mucosa-targeted DNA vaccination. Trends Immunol. 2001;22:646-648.
21. Akira S, Sato S. Toll-like receptors and their signaling mechanisms. Scand J Infect Dis. 2003;35:555-562.
22. Yamamoto M, Takeda K, Akira S. TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol. 2004;40:861-868.
23. Di Marzio L, Russo FP, D'Alo S, et al. Apoptotic effects of selected strains of lactic acid bacteria on a human T leukemia cell line are associated with bacterial arginine deiminase and/or sphingomyelinase activities. Nutr Cancer. 2001;40:185-196.
24. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580-591.
25. Anton P, O'Connell J, O'Connell D, et al. Mucosal subepithelial binding sites for the bacterial chemotactic peptide, formyl-methionyl-leucyl-phenylalanine (FMLP). Gut. 1998;42:374-379.
26. Girardin SE, Travassos LH, Herve M, et al. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem. 2003; 278:41702-41708.
27. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem. 2003;278:5509-5512.
28. Chamaillard M, Hashimoto M, Horie Y, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol. 2003;4:702-707.
29. Madsen K, Jijon H, Yeung H, et al. DNA from probiotic bacteria exerts anti-inflammatory actions on intestinal epithelial cells by inhibition of NF-kB. Gastroenterology. 2002;122:A546.
30. Akhtar M, Watson JL, Nazli A, et al. Bacterial DNA evokes epithelial IL-8 production by a MAPK-dependent, NF-kappaB-independent pathway. FASEB J. 2003;17:1319-1321.
31. Rachmilewitz D, Karmeli F, Takabayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology. 2002;122:1428-1441.
32. Ruseler-van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut. 1994;35:658-664.
33. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
34. Mimura T, Rizzello F, Schreiber S, et al. Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis: a randomised, placebo-controlled, double-blind trial. Supplement to Gastroenterology. 2002;122:A81.
35. Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003;17:509-515.
36. Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol. 2003;38:409-414.
37. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202-1209.
38. Gupta P, Andrew H, Kirschner BS, et al. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 2000;31:453-457.
39. McCarthy J, O'Mahony L, Dunne C, et al. An open trial of a novel probiotic as an alternative to steroids in mild/moderately active Crohn's disease. Gut. 2001;49(suppl III):2447.
40. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol. 1997;25:653-658.
41. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45:1462-1464.
42. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51:405-409.
43. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology. 2000;118:A781.
44. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995;108:1617-1621.
45. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-639.
46. Fedorak RN, Gionchetti P, Campieri M, et al. VSL3 Probiotic mixture induces remission in patients with active ulcerative colitis. Gastroenterology. 2003;124:A377.
47. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:697-698.
48. Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003;37:42-47.
49. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853-858.
50. Kruis W, Fric P, Stolte M. Maintenance of remission in ulcerative colitis is equality effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology. 2001;120:A127.
51. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-1108.
52. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22:56-63.
53. Schotte L, Steidler L, Vandekerckhove J, et al. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol. 2000;27:761-765.
54. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352-1355.
55. Steidler L, Neirynck S, Huyghebaert N, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol. 2003;21:785-789.
56. Borriello SP, Hammes WP, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36:775-780.
57. Gasser F. Safety of lactic-acid bacteria and their occurrence in human clinical infections. Bulletin de L'Institut Pasteur. 1994;92:45-67.
58. Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in southern Finland, 1989-1992. Clin Infect Dis. 1996;22:564-566.
59. Salminen MK, Tynkkynen S, Rautelin H, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 2002;35:1155-1160.
60. Statistics Finland. Finland in figures. Helsinki: Library of Statistics. 2000.
61. Husni RN, Gordon SM, Washington JA, et al. Lactobacillus bacteremia and endocarditis: review of 45 cases. Clin Infect Dis. 1997;25:1048-1055.
62. Wolf BW, Wheeler KB, Ataya DG, et al. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem Toxicol. 1998;36:1085-1094.
63. Patel R, Cockerill FR, Porayko MK, et al. Lactobacillemia in liver transplant patients. Clin Infect Dis. 1994;18:207-212.
64. Antony SJ, Stratton CW, Dummer JS. Lactobacillus bacteremia: description of the clinical course in adult patients without endocarditis. Clin Infect Dis. 1996;23:773-778.
65. Piarroux R, Millon L, Bardonnet K, et al. Are live saccharomyces yeasts harmful to patients? Lancet. 1999;353:1851-1852.
66. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis. 1999;28:1159-1160.
67. Pletincx M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr. 1995;21:113-115.
68. Horwitch CA, Furseth HA, Larson AM, et al. Lactobacillemia in three patients with AIDS. Clin Infect Dis. 1995;21:1460-1462.
69. Chomarat M, Espinouse D. Lactobacillus rhamnosus septicemia in patients with prolonged aplasia receiving ceftazidime-vancomycin. Eur J Clin Microbiol Infect Dis. 1991;10:44.
70. Pedone CA, Bernabeu AO, Postaire ER, et al. The effect of supplementation with milk fermented by Lactobacillus casei (strain DN-114001) on acute diarrhoea in children attending day care centres. Int J Clin Pract. 1999;53:179-184.
71. Vanderhoof JA, Young RJ. Use of probiotics in childhood gastrointestinal disorders. J Pediatr Gastroenterol Nutr. 1998;27:323-332.
72. Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30:54-60.
73. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut. 2003;52:988-997.
74. Ouwehand AC, Lagstrom H, Suomalainen T, et al. Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab 2002;46(3-4):159-162.
75. Mack DR, Ahrne S, Hyde L, et al. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52:827-833.
76. Lievin-Le Moal V, Amsellem R, Servin AL, et al. Lactobacillus acidophilus (strain LB) from the resident adult human gastrointestinal microflora exerts activity against brush border damage promoted by a diarrhoeagenic Escherichia coli in human enterocyte-like cells. Gut. 2002; 50:803-811.
77. Garcia-Lafuente A, Antolin M, Guarner F, et al. Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut. 2001;48:503-507.
78. Freitas M, Tavan E, Cayuela C, et al. Host-pathogens cross-talk. Indigenous bacteria and probiotics also play the game. Biol Cell. 2003;95: 503-506.
79. Kaila M, Isolauri E, Soppi E, et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res. 1992;32:141-144.
80. Majamaa H, Isolauri E, Saxelin M, et al. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr. 1995;20:333-338.
81. Fang H, Elina T, Heikki A, et al. Modulation of humoral immune response through probiotic intake. FEMS Immunol Med Microbiol. 2000; 29:47-52.
82. Gill HS, Cross ML, Rutherford KJ, et al. Dietary probiotic supplementation to enhance cellular immunity in the elderly. Br J Biomed Sci. 2001; 58:94-96.
83. Cano PG, Aguero G, Perdigon G. Immunological effects of yogurt addition to a re-nutrition diet in a malnutrition experimental model. J Dairy Res. 2002;69:303-316.
84. Park JH, Um JI, Lee BJ, et al. Encapsulated Bifidobacterium bifidum potentiates intestinal IgA production. Cell Immunol. 2002;219:22-27.
85. Shu Q, Gill HS. Immune protection mediated by the probiotic Lactobacillus rhamnosus HN001 (DR20) against Escherichia coli O157:H7 infection in mice. FEMS Immunol Med Microbiol. 2002;34:59-64.
86. Braat H, De Jong EC, Van Den Brande JM, et al. Dichotomy between Lactobacillus rhamnosus and Klebsiella pneumoniae on dendritic cell phenotype and function. J Mol Med. 2004;82:197-205.
87. Roller M, Rechkemmer G, Watzl B. Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rats. J Nutr. 2004;134:153-156.
88. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science. 2000; 289:1560-1563.
89. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem. 2002;277:50959-50965.
90. Kullisaar T, Zilmer M, Mikelsaar M, et al. Two antioxidative lactobacilli strains as promising probiotics. Int J Food Microbiol. 2002;72:215-224.
91. He F, Ouwehand AC, Isolauri E, et al. Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants. FEMS Immunol Med Microbiol. 2001;30:43-47.
92. Lee YK, Puong KY. Competition for adhesion between probiotics and human gastrointestinal pathogens in the presence of carbohydrate. Br J Nutr. 2002;88(suppl 1):S101-S108.
93. Boudeau J, Glasser AL, Julien S, et al. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther. 2003;18:45-56.
94. Fernandez MF, Boris S, Barbes C. Probiotic properties of human lactobacilli strains to be used in the gastrointestinal tract. J Appl Microbiol. 2003;94:449-455.
95. Huang Y, Adams MC. An in vitro model for investigating intestinal adhesion of potential dairy propionibacteria probiotic strains using cell line C2BBe1. Lett Appl Microbiol. 2003;36:213-216.
96. Kos B, Suskovic J, Vukovic S, et al. Adhesion and aggregation ability of probiotic strain Lactobacillus acidophilus M92. J Appl Microbiol. 2003; 94:981-987.
97. Lee YK, Puong KY, Ouwehand AC, et al. Displacement of bacterial pathogens from mucus and Caco-2 cell surface by lactobacilli. J Med Microbiol. 2003;52:925-930.
98. Rinkinen M, Jalava K, Westermarck E, et al. Interaction between probiotic lactic acid bacteria and canine enteric pathogens: a risk factor for intestinal Enterococcus faecium colonization? Vet Microbiol. 2003;92 (1-2):111-119.
99. Schaer-Zammaretti P, Ubbink J. Imaging of lactic acid bacteria with AFM - elasticity and adhesion maps and their relationship to biological and structural data. Ultramicroscopy. 2003;97(1-4):199-208.
100. Michail S, Abernathy F. Lactobacillus plantarum reduces the in vitro secretory response of intestinal epithelial cells to enteropathogenic Escherichia coli infection. J Pediatr Gastroenterol Nutr. 2002;35:350-355.
101. Hashizume K, Tsukahara T, Yamada K, et al. Megasphaera elsdenii JCM1772T normalizes hyperlactate production in the large intestine of fructooligosaccharide-fed rats by stimulating butyrate production. J Nutr. 2003;133:3187-3190.
102. Coconnier MH, Lievin V, Lorrot M, et al. Antagonistic activity of Lactobacillus acidophilus LB against intracellular Salmonella enterica serovar Typhimurium infecting human enterocyte-like Caco-2/TC-7 cells. Appl Environ Microbiol. 2000;66:1152-1157.
103. Lievin V, Peiffer I, Hudault S, et al. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut. 2000;47:646-652.
104. Caridi A. Selection of Escherichia coli-inhibiting strains of Lactobacillus paracasei subsp. paracasei. J Ind Microbiol Biotechnol. 2002;29: 303-308.
105. Eijsink VG, Axelsson L, Diep, DB, et al. Production of class II bacteriocins by lactic acid bacteria; an example of biological warfare and communication. Antonie Van Leeuwenhoek. 2002;81(1-4):639-654.
106. Flynn S, van Sinderen D, Thornton GM, et al. Characterization of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. salivarius UCC118. Microbiology. 2002;148:973-984.
107. Park SH, Itoh K, Fujisawa T. Characteristics and identification of enterocins produced by Enterococcus faecium JCM 5804T. J Appl Microbiol. 2003;95:294-300.
108. Xiao H, Chen X, Chen M, et al. Bovicin HJ50, a novel lantibiotic produced by Streptococcus bovis HJ50. Microbiology. 2004;150:103-108.
109. Kato I, Endo-Tanaka K, Yokokura T. Suppressive effects of the oral administration of Lactobacillus casei on type II collagen-induced arthritis in DBA/1 mice. Life Sci. 1998;63:635-644.
110. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology. 1999; 116:1107-1114.
111. Haller D, Bode C, Hammes WP, et al. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte cocultures. Gut. 2000;47:79-87.
112. Maassen CB, van Holten-Neelen C, Balk F, et al. Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine. 2000;18:2613-2623.
113. Kalliomaki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357:1076-1079.
114. von der Weid T, Bulliard C, Schiffrin EJ. Induction by a lactic acid bacterium of a population of CD4(+) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10. Clin Diagn Lab Immunol. 2001;8:695-701.
115. He F, Morita H, Ouwehand AC, et al. Stimulation of the secretion of pro-inflammatory cytokines by Bifidobacterium strains. Microbiol Immunol. 2002;46:781-785.
116. Lammers KM, Helwig U, Swennen E, et al. Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol. 2002; 97:1182-1186.
117. Morita H, He F, Fuse T, et al. Adhesion of lactic acid bacteria to caco-2 cells and their effect on cytokine secretion. Microbiol Immunol. 2002; 46:293-297.
118. Morita H, He F, Fuse T, et al. Cytokine production by the murine macrophage cell line J774.1 after exposure to lactobacilli. Biosci Biotechnol Biochem. 2002;66:1963-1966.
119. Perdigon G, Maldonado Galdeano C, Valdez JC, et al. Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr. 2002;56(suppl 4):S21-S26.
120. Lammers KM, Brigidi P, Vitali B, et al. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol. 2003;38:165-172.
121. McCarthy J, O'Mahony L, O'Callaghan L, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut. 2003;52:975-980.
122. Schultz M, Linde HJ, Lehn N, et al. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res. 2003;70:165-173.
123. Vinderola CG, Medici M, Perdigon G. Relationship between interaction sites in the gut, hydrophobicity, mucosal immunomodulating capacities and cell wall protein profiles in indigenous and exogenous bacteria. J Appl Microbiol. 2004;96:230-243.
124. Prioult G, Fliss I, Pecquet S. Effect of probiotic bacteria on induction and maintenance of oral tolerance to beta-lactoglobulin in gnotobiotic mice. Clin Diagn Lab Immunol. 2003;10:787-792.
125. Gionchetti P, Amadini C, Rizzello F, et al. Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther. 2002;16(suppl 4):13-19.